NEVRO CORP. (NYSE:NVRO) Files An 8-K Entry into a Material Definitive Agreement

NEVRO CORP Exhibit
EX-10.1 2 d710346dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 AGREEMENT This agreement (this “Agreement”) is made and entered into as of March 19,…
To view the full exhibit click here

About NEVRO CORP. (NYSE:NVRO)

Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy offers back pain relief in addition to leg pain relief. HF10 therapy also provides pain relief without paresthesia. HF10 therapy offers benefits to patients, physicians and hospitals. The Company’s Senza is designed to create electrical impulses from 2 hertz to 10 kilohertz (kHz), including its HF10 therapy. HF10 therapy delivers waveforms at 10 kHz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads, a trial stimulator, an implantable pulse generator (IPG), surgical tools, a clinician laptop programmer, a patient remote control and a mobile charger.